Self-assembled siRNA-PLGA conjugate micelle as RCAS1 gene silencing therapy for intractable cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K18945
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical pharmacy
• Research Institution: Fukuoka University
• Principal Investigator: Hazekawa Mai 福岡大学, 薬学部, 助教 (10509186)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: ミセル / PLGA / 卵巣がん / Glypican-3

Outline of Final Research Achievements

It was recently reported that Glypican-3 (GPC-3) was specifically overexpressed in ovarian cancer. We focused on GPC-3 gene silencing for ovarian cancer therapy employing a siRNA delivery system. The purpose of our study was to prepare self-assembled siRNA-poly (D,L-lactic-co-glycolic acid) (PLGA) hybrid conjugate micelles for GPC-3 gene silencing. For in vivo experiments, micelles were administrated intraperitoneally in a mouse model of peritoneal dissemination. At 14 days after treatment with micelles, micelles decreased the volume of peritoneal fluid and the number of tumor nodes in the mesentery, compared with in the control. Self-assembled siRNA-PLGA hybrid conjugate micelles are, thus, potentially useful as an efficient siRNA delivery system for ovarian cancer therapy.

Free Research Field

医療系薬学、医療薬剤学